Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822348 | 1.00 | KDM4E (0.79) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL6644034 | 0.98 | KDM4E (0.75) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL27980382 | 0.89 | KDM4E (1.00) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL10857129 | 0.89 | — | — | |
| SCHEMBL3539236 | 0.81 | KDM4E (0.76) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL9476242 | 0.81 | KDM4E (0.76) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL9516706 | 0.81 | KDM4E (0.76) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL3393821 | 0.79 | KDM4E (0.74) | KDM4ESMN1; SMN2HTTSLC2A1ANPEP | |
| SCHEMBL12632978 | 0.79 | KDM4E (0.50) | KDM4ESMN1; SMN2HTTSLC2A1KMT2A | |
| SCHEMBL7307797 | 0.79 | KDM4E (0.50) | KDM4ESMN1; SMN2HTTSLC2A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9003020-A | — | — | None | — | — | JP | disclosed |
| EP-2889073-B1 | ACID GAS REMOVAL METHOD | TOSHIBA KK (JP) | 2020-09-02 | — | — | EP | disclosed |
| CN-105001880-B | Aligning agent for liquid crystal and liquid crystal display element | JSR株式会社 | 2018-06-15 | — | — | CN | disclosed |
| CN-103849406-B | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, phase difference film, manufacturing method for the phase difference film, polymer, and compound | JSR株式会社 | 2017-03-22 | — | — | CN | disclosed |
| CN-103289712-B | Crystal aligning agent, liquid crystal orienting film and liquid crystal display cells | JSR株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-20150298054-A1 | CARBON DIOXIDE RECOVERY APPARATUS AND CARBON DIOXIDE RECOVERY METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2933008-A1 | CARBON DIOXIDE RECOVERY APPARATUS AND CARBON DIOXIDE RECOVERY METHOD - ABSORBENT REGENERATION INVOLVING PHASE SEPARATION | Kabushiki Kaisha Toshiba (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150246313-A1 | CARBON DIOXIDE RECOVERY APPARATUS AND CARBON DIOXIDE RECOVERY METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2015-09-03 | — | — | US | disclosed |
| EP-2913092-A1 | Carbon dioxide recovery apparatus and carbon dioxide recovery method | KABUSHIKI KAISHA TOSHIBA (JP) | 2015-09-02 | — | — | EP | disclosed |
| EP-2889073-A1 | Acid gas removal apparatus and acid gas removal method | Kabushiki Kaisha Toshiba (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20110040046-A1 | ADDUCTS OF EPOXY RESINS AND PROCESS FOR PREPARING THE SAME | BLUE CUBE IP LLC | 2011-02-17 | — | — | US | disclosed |
| US-7687507-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-6890929-B2 | Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease | PFIZER, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1087970-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-6610847-B2 | Tyrosine kinase inhibitors; immunosuppressants | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| JP-H093020-A | N-HALOGENATED HINDERED AMINE COMPOUND | LION CORP | 1997-01-07 | — | — | JP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | KDM4E 1999/4885SMN1; SMN2 3484/4885HTT 4247/4885 |
| US-20050171128-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, JAK2 | KDM4E 1567/4885SMN1; SMN2 3594/4885HTT 4169/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | KDM4E 1999/4885SMN1; SMN2 3484/4885HTT 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.